Sign in

    John Young • Canaccord Genuity

    John Young's questions to iRhythm Technologies Inc (IRTC) leadership

    John Young's questions to iRhythm Technologies Inc (IRTC) leadership • Q1 2025

    Question

    John Young asked if the overall MCT market is growing and if iRhythm is benefiting from post-ablation monitoring, particularly with the expansion of Pulsed Field Ablation (PFA).

    Answer

    CEO Quentin Blackford responded that it is difficult to isolate any benefit from PFA and believes the overall MCT market is likely to be 'slightly flat' over time due to CMS pricing pressure. He emphasized that iRhythm's growth opportunity is in taking share from competitors in existing accounts, noting every 10 points of share gain represents $80M-$100M in revenue.

    Ask Fintool Equity Research AI

    John Young's questions to iRhythm Technologies Inc (IRTC) leadership • Q4 2024

    Question

    John Young asked whether any revenue from the sleep apnea initiative is included in the 2025 guidance and how management is thinking about contributions from this and other adjacent market opportunities.

    Answer

    CEO Quentin Blackford confirmed that there is no revenue from sleep apnea included in the 2025 guidance. He expressed confidence in the company's 'right to win' in the space by leveraging its existing digital platform for primary care physicians. However, following a prudent approach, management will wait for revenue to materialize before incorporating it into financial forecasts.

    Ask Fintool Equity Research AI

    John Young's questions to Merit Medical Systems Inc (MMSI) leadership

    John Young's questions to Merit Medical Systems Inc (MMSI) leadership • Q1 2025

    Question

    John Young asked about the company's ability to raise prices to offset tariffs and for commentary on the U.S. performance of the WRAPSODY device during the quarter.

    Answer

    EVP and CFO Raul Parra explained that while pricing is a lever in their CGI program, they are taking a measured approach to avoid disrupting customer relationships amid tariff uncertainty. Chairman and CEO Fred Lampropoulos expressed continued enthusiasm for WRAPSODY, stating that its progress on clinical data, reimbursement, and adoption is meeting all expectations.

    Ask Fintool Equity Research AI

    John Young's questions to Merit Medical Systems Inc (MMSI) leadership • Q4 2024

    Question

    John Young of Canaccord Genuity asked for confirmation on the timely filing of the Wrapsody TPT application, the status of prior OEM supply chain challenges, and the company's ability to mitigate potential tariffs by moving manufacturing.

    Answer

    Executive Fred Lampropoulos confirmed that both the NTAP and TPT applications for Wrapsody were filed on time. Executive Raul Parra stated that previous OEM supply chain issues are now largely resolved. Regarding tariffs, both executives explained that making significant manufacturing moves is impractical given the fluid situation. They are monitoring developments closely but will not overreact, instead focusing on execution and adjusting as official policies are announced.

    Ask Fintool Equity Research AI

    John Young's questions to Merit Medical Systems Inc (MMSI) leadership • Q3 2024

    Question

    John Young of Canaccord Genuity inquired about the potential 'halo effect' of the Cook Medical acquisition on Merit's broader Cardiac Intervention portfolio in 2025. He also sought clarification on the WRAPSODY reimbursement strategy, specifically the timeline for the NTAP add-on payment and whether product pricing would assume its approval.

    Answer

    Joseph Wright, an executive, confirmed the strategic rationale is to create an anchor portfolio to build out an EP-focused sales force, driving both acquired and existing product revenue. Raul Parra, an executive, added the deal would contribute approximately $40 million in annualized revenue in fiscal 2025. Regarding WRAPSODY, Joseph Wright stated the company has submitted for NTAP and will price the product with the assumption of receiving it, noting the TPT application would be submitted post-FDA approval.

    Ask Fintool Equity Research AI

    John Young's questions to STAAR Surgical Co (STAA) leadership

    John Young's questions to STAAR Surgical Co (STAA) leadership • Q4 2024

    Question

    John Young of Canaccord asked for feedback from STAAR's on-the-ground sales force in China and how their incentives are being adjusted to manage the distributor dynamics. He also inquired about the current number of U.S. 'Fast Lane' accounts and any updates on U.S. growth initiatives given the company's new cost-saving measures.

    Answer

    CEO Tom Frinzi stated that the China team's incentives are being shifted to focus on driving sell-through procedure volume rather than just sell-in to distributors. CFO Patrick Williams reported strong U.S. performance, with approximately 13 'Fast Lane' accounts now established. Both executives emphasized a continued focus on U.S. growth, including initiatives to educate optometrists and conduct a head-to-head clinical study to grow the overall refractive market, not just take share from a declining laser vision correction market.

    Ask Fintool Equity Research AI

    John Young's questions to STAAR Surgical Co (STAA) leadership • Q2 2024

    Question

    John Young of Canaccord Genuity asked for an update on the 'fast lane' accounts mentioned last quarter, inquiring how many new ones were identified and about plans for signing more strategic alliances in the second half of the year.

    Answer

    Executive Thomas G. Frinzi reported that the company has now signed 9 new strategic agreements in the U.S. this year, up from 6 reported last quarter, against a target list of 15. Executive Patrick Williams added that they are experiencing a 'halo effect,' with other accounts now proactively approaching them to partner.

    Ask Fintool Equity Research AI